A client has a fungal infection caused by Candida albicans. If susceptible, which medication is the first option for the nurse to recommend?

Introduction: Candida albicans is a common opportunistic yeast. Treatment selection depends on the severity and location of the infection. For most systemic or localized candidal infections, an oral or intravenous azole antifungal is preferred due to its efficacy and relatively low toxicity profile compared to more aggressive agents. A. Amphotericin B is a "polyene" antifungal used for severe, life-threatening systemic fungal infections. It is nicknamed "Ampho-terrible" due to its high toxicity, including nephrotoxicity and severe infusion reactions. It is not the "first option" for a typical Candida infection unless it is refractory to other treatments. B. Imipenem-cilastatin is a broad-spectrum carbapenem antibiotic. It is used to treat bacterial infections, not fungal infections. Using an antibacterial agent for a Candida (yeast) infection would be ineffective and could potentially worsen the fungal overgrowth by killing competing normal flora. C. Griseofulvin is used specifically for dermatophyte infections (tinea) of the skin, hair, and nails. It is not effective against Candida albicans. Its mechanism involves binding to keratin, making it useful for superficial fungal infections but inappropriate for candidiasis. D. FLUCONAZOLE is often the FIRST OPTION for treating CANDIDA ALBICANS. It is highly effective, well-tolerated, and available in both oral and IV formulations. It works by inhibiting the synthesis of ergosterol, an essential component of the fungal cell membrane, leading to cell death.